vs
Side-by-side financial comparison of Evaxion A/S (EVAX) and Check-Cap Ltd (MBAI). Click either name above to swap in a different company.
Check-Cap Ltd is the larger business by last-quarter revenue ($47.9K vs $37.0K, roughly 1.3× Evaxion A/S). Check-Cap Ltd runs the higher net margin — 2.3% vs -13056.8%, a 13059.0% gap on every dollar of revenue.
Evaxion A/S is a Danish clinical-stage biotechnology company that leverages proprietary artificial intelligence platforms to develop targeted immunotherapies. Its core pipeline includes personalized cancer vaccines, off-the-shelf immuno-oncology treatments, and novel infectious disease therapies, advancing programs through partnerships with global pharmaceutical stakeholders.
Check-Cap Ltd is a clinical-stage medical technology company specializing in non-invasive colorectal cancer screening solutions. Its core offering is an ingestible imaging capsule that requires no prior bowel preparation, targeting global healthcare markets to boost accessibility of early colon cancer detection for at-risk patient groups.
EVAX vs MBAI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.0K | $47.9K |
| Net Profit | $-4.8M | $1.1K |
| Gross Margin | — | 5.2% |
| Operating Margin | -11729.7% | 2.9% |
| Net Margin | -13056.8% | 2.3% |
| Revenue YoY | -76.0% | — |
| Net Profit YoY | 22.1% | 100.0% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $47.9K | ||
| Q2 25 | $37.0K | — | ||
| Q2 24 | $154.0K | — | ||
| Q2 23 | $0 | — |
| Q4 25 | — | $1.1K | ||
| Q2 25 | $-4.8M | — | ||
| Q2 24 | $-6.2M | — | ||
| Q2 23 | $-5.7M | — |
| Q4 25 | — | 5.2% | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 2.9% | ||
| Q2 25 | -11729.7% | — | ||
| Q2 24 | -2974.7% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 2.3% | ||
| Q2 25 | -13056.8% | — | ||
| Q2 24 | -4024.7% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | $-0.21 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $94.3K |
| Total DebtLower is stronger | $9.2M | — |
| Stockholders' EquityBook value | $6.2M | $1.4K |
| Total Assets | $22.4M | $184.9K |
| Debt / EquityLower = less leverage | 1.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $94.3K | ||
| Q2 25 | $14.7M | — | ||
| Q2 24 | $8.0M | — | ||
| Q2 23 | $7.1M | — |
| Q4 25 | — | — | ||
| Q2 25 | $9.2M | — | ||
| Q2 24 | $8.4M | — | ||
| Q2 23 | $8.2M | — |
| Q4 25 | — | $1.4K | ||
| Q2 25 | $6.2M | — | ||
| Q2 24 | $1.3M | — | ||
| Q2 23 | $2.5M | — |
| Q4 25 | — | $184.9K | ||
| Q2 25 | $22.4M | — | ||
| Q2 24 | $15.2M | — | ||
| Q2 23 | $16.8M | — |
| Q4 25 | — | — | ||
| Q2 25 | 1.48× | — | ||
| Q2 24 | 6.72× | — | ||
| Q2 23 | 3.25× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-89.2K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -81.94× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-89.2K | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -81.94× | ||
| Q2 25 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
